ONCAlert | 2018 ASCO Annual Meeting

A Preview of the 2013 ASH Annual Meeting

Marcel R.M. van den Brink, MD, PhD
Published Online: 2:35 PM, Thu December 5, 2013
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Alan N. Houghton Chair, Memorial Sloan-Kettering Cancer Center, highlights two studies that will be presented at the 2013 American Society of Hematology (ASH) Meeting.

Abstract 69
Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy
  • Research in this area has come to fruition in the last year in ALL
  • This genetically manipulated T cell therapy can be used in patients with ALL who have failed other therapies
  • This therapy could provide a ‘bridge’ to life-saving bone marrow transplant
Abstract 852
Combining Ibrutinib With R-CHOP: Updated Results From a Phase 1b Study In Treatment-Naïve Patients With CD20-Positive B-Cell NHL
  • Ibrutinib has been used in a variety of B-cell tumors
  • Results from this study are particularly promising because response rates were higher than what would be normally seen in this space

<<< Back to the conference page

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.